Becker’s is thrilled to honor these Hispanic and Latino healthcare leaders. Diverse leadership in healthcare culminates in a more comprehensive, seamless experience for both patients and providers alike.
Category: Static
Hospital president out after Lifespan trims 20% of executive roles
Providence, R.I.-based Lifespan has reduced executive positions by 20%, John Fernandez, Lifespan president and CEO, said in a statement shared with Becker’s.
CEO pay dips in 2023
CEO compensation declined significantly in 2023 when compared to the stock market’s relative steadiness, according to a recent report.
5 reasons Ozempic's price could drop
As the demand for GLP-1 drugs grows, there are several factors emerging that could result in its price decreasing.
Cardinal Health to acquire Integrated Oncology Network for $1.1B
Cardinal Health plans to acquire Integrated Oncology Network for $1.115 billion in cash, expanding its business into oncology services, according to a Sept. 20 news release from the company.
Chemotherapy patients under Medicare Advantage use fewer resources: Study
Medicare Advantage beneficiaries used what amounted to $8,718 less in resources than traditional Medicare beneficiaries within six months of beginning chemotherapy treatment, according to a study published Sept. 20 in JAMA Network Open.
FTC sues nation's 3 largest PBMs: 10 notes
After weeks of internal disagreements at the Federal Trade Commission about pharmacy benefit managers, the agency said Sept. 20 that it is suing CVS Caremark, Optum Rx and Express Scripts over allegedly inflating insulin prices.
HCA Utah hospital names COO
Rustin Beck has been named COO of Lakeview Hospital in Bountiful, Utah, according to a Sept. 20 LinkedIn post from the hospital.
Change Healthcare overhauls systems after cyberattack
UnitedHealth Group subsidiary Change Healthcare had to “start over” with its computer systems following a ransomware attack in February, Cyberscoop reported Sept. 19.
Drugmakers to discontinue fentanyl 'lollipops': FDA
Drugmakers will discontinue the sales of a controversial class of fentanyl-based painkillers by the end of September, the FDA confirmed Sept. 16.
